Quest Diagnostics has partnered with Paige to develop software products leveraging artificial intelligence (AI) to enhance and expedite the pathologic diagnoses of cancer and various other diseases.
Using Paige’s machine learning capabilities, the partnership will analyse pathology diagnostic data and digitised slides from Quest as well as its AmeriPath and Dermpath units to identify markers of cancer and other indications.
Go deeper with GlobalData
Using this data, the companies plan to create new software products that can be used for disease diagnoses by pathologists and oncologists, among others.
Furthermore, Quest and Paige anticipate licensing the insights to biopharmaceutical and research organisations for discovering biomarkers, as well as the research and development of drugs and companion diagnostics.
In the initial stage, the partnership will work on solid tumours, including prostate, breast, colorectal and lung cancers.
As per the deal, the companies will share revenue for meeting specific product and commercial milestones, as well as carry out combined marketing and research.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataQuest also holds the rights to use potentially approved software products in its pathology processes.
Further terms of the collaboration were not divulged by the companies.
Paige CEO Leo Grady said: “We are excited to collaborate with Quest to create new software products that can deliver faster, more accurate and more informed clinical insights to patients than what is possible today.
“Given Quest’s vast footprint in the diagnostic space, this collaboration will enable us to ensure broad adoption of the clinical products and biomarkers we’re building.”
Quest noted that AI-based computational pathology can detect known patterns in tissue that signify disease and can detect new markers, including ones that cannot be identified by the naked eye.
In addition, the latest collaboration is in line with Quest’s intent to grow its digital pathology network for pathologists across the US.
In February, Quest unveiled a new Covid-19 semi-quantitative serology testing service that helps in offering insight into a person’s immune response to prior SARS-CoV-2 infection or Covid-19 vaccination.
In a separate development, iHealthScreen has received CE mark for its iPredict AI Eye Screening System, which automatically screens for diabetic retinopathy, age-related macular degeneration and glaucoma suspect and delivers instant report of actionable results.
